A three-year pulmonary rehabilitation program — a combination of aerobic, resistance, and breathing exercises — helped to maintain lung and…
Articles by Patricia Inácio, PhD
Exposure to secondhand smoke, dust, or asbestos in the workplace is linked to a significantly higher risk of developing…
Researchers have discovered the existence of unique subtypes of epithelial cells in the lungs of people with pulmonary fibrosis…
Idiopathic pulmonary fibrosis (IPF) patients taking antifibrotic therapies Ofev (nintedanib) or Esbriet (pirfenidone) had a mortality risk that was 37%…
A real-world, multi-center study in Poland confirms the effectiveness and safety of two-year treatment with Esbriet (pirfenidone) for people with …
Lung evaluations via a CT scan might help predict the mortality risk in idiopathic pulmonary fibrosis (IPF) patients more…
The Phase 2b GALACTIC-1 trial testing Galecto’s candidate GB0139 as an inhalation therapy for idiopathic pulmonary fibrosis (IPF)…
A cell therapy based on human and rat lung progenitor cells — called lung spheroid cells — reduced scarring (fibrosis)…
The Centers for Medicare and Medicaid Services (CMS) has waived all requirements for in-person testing and signature at delivery…
A clinical trial in the U.K. is recruiting people with idiopathic pulmonary fibrosis (IPF) to test Trevi Therapeutics’…